Dihexa for Cognitive Enhancement (ZERO Human Trials - Prodrug FAILED Phase 2/3) — Brain
CRITICAL WARNING: Dihexa has ZERO human clinical trials. Pharmaceutical prodrug (Fosgonimeton) FAILED all Phase 2/3 trials. Potent synaptogenic peptide with theoretical cancer risk via c-Met oncogene activation.
Overview
CRITICAL EVIDENCE UPDATE (2024): Dihexa (PNB-0408) has ZERO published human clinical trials. Fosgonimeton (ATH-1017), the pharmaceutical prodrug developed by Athira Pharma, FAILED all Phase 2/3 trials: ACT-AD (2022), LIFT-AD (Sept 2024, P=0.70 primary endpoint), and SHAPE (Parkinson's). Development paused Sept 2024. Research integrity scandal: CEO resigned Oct 2021 after investigation found altered images in foundational dissertation research. Dihexa binds to HGF, activates c-Met receptors (a known oncogene), and promotes synaptogenesis. Animal studies show 7 million times more potent than BDNF in neurotropic assays. Despite positive Phase 1 tolerability and ERP P300 biomarker signals in fosgonimeton, ZERO clinical efficacy has been demonstrated in any human trial. All current 'clinical use' of Dihexa is uncontrolled experimentation with zero validated dosing or safety data.
Indications
- Cognitive decline and memory impairment (PRECLINICAL ONLY)
- Alzheimer's disease and dementia (EXPERIMENTAL - Prodrug FAILED Phase 2/3)
- Traumatic brain injury (TBI) recovery (ANIMAL DATA ONLY)
- Learning enhancement and synaptic plasticity (NO HUMAN EVIDENCE)
- Age-related cognitive decline (UNVALIDATED)
- Neurodegenerative disease support (PRODRUG FAILED 3 TRIALS)
Mechanism of Action
Synaptic loss, reduced neuroplasticity, or neurodegeneration impairs learning and memory formation
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Dihexa | 1-5 mg | Once daily (morning) | Microdose approach for new users, assess tolerance |
| Dihexa | 5-10 mg | Once daily (morning) | Common starting dose for cognitive enhancement |
| Dihexa | 10-20 mg | Once daily (morning) | Higher dose for therapeutic applications, medical supervision required |
| Dihexa 20 mg/gm | Apply to inner forearms | Once daily (morning) | Popular alternative to oral, steady absorption |
| Dihexa compounded | Varies by formulation | Once or twice daily | Direct brain access, requires compounding pharmacy |
Evidence Grade
GRADE D
Safety & Contraindications
- ZERO HUMAN CLINICAL TRIALS of Dihexa itself - ALL data is preclinical
- FOSGONIMETON (prodrug) FAILED Phase 2 ACT-AD (2022), Phase 2/3 LIFT-AD (Sept 2024), Phase 2 SHAPE trials
- DEVELOPMENT PAUSED by Athira Pharma September 2024 following trial failures
- CANCER RISK: HGF/c-Met is a known ONCOGENE pathway - theoretical tumor/metastasis risk
- RESEARCH INTEGRITY: Foundational dissertation research had altered images (CEO resigned Oct 2021)
- NO VALIDATED DOSING: All 'clinical dosing' (5-20mg) is based on user reports, not clinical data
- 12-DAY HALF-LIFE creates prolonged systemic exposure with unknown consequences
- UNCONTROLLED EXPERIMENTATION: Anyone using Dihexa is a test subject without safety monitoring
- Potential for maladaptive brain wiring with overstimulation
- Contraindicated in seizure disorders, psychiatric conditions, or any history of cancer
- Long-term safety effects completely unknown - no long-term animal or human studies exist